our objectives were to examine ACEI/ARB prescription rates at hospital discharge based on current ACC/AHA guideline criteria, to evaluate temporal trends of ACEI/ARB use in patients hospitalized with ACS, and to assess patient and hospital factors associated with ACEI/ARB use.
Methods

Study Population
The Get With the Guidelines (GWTG)-coronary artery disease (CAD) program is a quality improvement registry designed to capture guideline-based recommendations with the aim to improve quality of care and outcomes in patients hospitalized with CAD. Details of the GWTG-CAD program have been previously described. 17 From January 2005 to December 2009, 168 815 patients who participated in GWTG-CAD and were discharged from 336 hospital sites with complete clinical data sets were selected using the electronic case record form Patient Management Tool (Outcome, Cambridge, MA). Of these, 50 709 non-ACS (ie, no evidence of unstable angina, non-ST-segment-elevation myocardial infarction [NSTEMI] , or ST-segment-elevation myocardial infarction [STEMI] ) patients were excluded. Additional exclusions were 30 178 patients who died, left against medical advice, or were discharged to another facility (ie, nursing care facility, rehabilitation center, hospice, and another hospital), 7299 with a contraindication (or history of contraindication) to ACEI/ARB therapy as documented in the medical chart (allergy, angioedema, anaphylactoid reactions, hyperkalemia, end-stage renal disease, cough, and pregnancy) and 388 who had missing class I or class IIa indication variables. The final study population included 80 241 patients admitted with an ACS from 311 hospitals who were alive at discharge, had an ACC/AHA class I or class IIa indication for treatment, and had no documented contraindications to ACEI/ARB therapy.
Participating hospitals in the GWTG-CAD program submitted the GWTG protocol to their local institutional review board for approval. Because the deidentified data for this study are used for quality improvement, a waiver of informed consent was granted under the Common Rule. The Duke Clinical Research Institute serves as the data analysis center for the GWTG-CAD program.
Objectives
The main objective of our analysis was to evaluate the frequency of ACEI/ARB prescription at discharge as defined by the ACC/AHA guidelines for patients with ACS. 14, 15 To assess appropriate ACEI/ ARB use, we divided patients by ACC/AHA class I (heart failure, LV dysfunction [LV ejection fraction, <40%], hypertension, diabetes mellitus, or chronic kidney disease) or class IIa recommendations (absence of LV dysfunction [LV ejection fraction, ≥40%], hypertension, diabetes mellitus, or chronic kidney disease).
14, 15 We also assessed ACEI/ARB use according to the type of ACS (ie, unstable angina, NSTEMI, and STEMI) and selection of in-hospital treatment (ie, medical therapy, percutaneous coronary intervention [PCI], or coronary artery bypass grafting [CABG]) after ACS. Clinical trials establishing the efficacy of ACEI/ARB in ACS did not exclude patients undergoing revascularization. As such, we included patients receiving PCI and CABG in the current analysis. Temporal trends in ACEI/ARB prescription rates at discharge were evaluated during the study period. Finally, patient and hospital characteristics associated with ACEI/ARB use at discharge were evaluated.
Statistical Analysis
Patient and hospital characteristics, measures, and outcomes were summarized descriptively by ACEI/ARB for ACC/AHA class indication. Pearson χ 2 test was used for categorical variables, and Wilcoxon test was used for continuous variables.
To examine the influencing factors on ACEI/ARB use at discharge further, a multivariable logistic regression model was fitted. The generalized estimating equation method with an exchangeable working correlation structure was used to account for within-hospital clustering. This method produces estimates similar to those from ordinary logistic regression, but the variances are adjusted for the correlation of outcomes within each hospital. A standard list of patient and hospital characteristics was entered into a multivariable model. Variables considered in the adjustment included age, sex, race, body mass index (only for class I group), insurance, medical histories of chronic obstructive pulmonary disease or asthma, diabetes mellitus (combined), CAD, heart failure, hypertension, hyperlipidemia, prior MI, peripheral vascular disease, renal insufficiency (as determined by the clinician), cerebrovascular accident/transient ischemic attack, depression, smoking, prior PCI or CABG, in-hospital procedures of CABG, PCI, hospital characteristics of bed size, region, hospital type (academic versus not), cardiothoracic surgery capability, and whether primary percutaneous transluminal coronary angioplasty was performed. Backward selection was used to eliminate highly insignificant factors (cutoff P=0.1). Odds ratios with 95% confidence intervals are presented.
Time trend in rate of patients receiving ACEI/ARB prescriptions was also examined descriptively and by multivariable logistic regression modeling. Year 2009 data were excluded for time trend analysis because of insufficient data. The analyses were performed on total patients and on class I or class IIa separately.
A P value <0.05 was considered significant for all tests. All statistical analyses were performed by the Duke Clinical Research Institute using SAS software (version 9.2; SAS Institute, Cary, NC).
Results
Our total study population included 80 241 patients admitted to a GWTG-CAD participating hospital (311 sites) who were alive on discharge and were eligible for ACEI/ARB therapy. Figure 1A demonstrates the prescription pattern of ACEI/ ARB according to ACS presentation by ACC/AHA class I and class IIa indication. Acute MI unspecified included both NSTEMI and STEMI during the time period when NSTEMI and STEMI were not coded separately. Prescription patterns were concordant with the risk of ACS presentation irrespective of ACC/AHA class I and class IIa indication. Figure 1B outlines the prescription pattern of ACEI/ARB according to assigned treatment after ACS by ACC/AHA class I and class IIa indication. In general, prescription rates for ACEI/ARB were low in the patient population with CABG irrespective of ACC/AHA class I or class IIa indication. Figure 2 shows the temporal trends of ACEI/ARB prescription from 2005 to 2008 in patients with ACS who met an ACC/ AHA class I and class IIa indication. ACEI/ARB therapy prescription increased from 76.7% to 84.6% (P<0.001) for class I indication and from 62.8% to 70.2% (P<0.001) for class IIa indication. On multivariate analysis, there were 17% and 12% increased odds of receiving an ACEI/ARB prescription (per calendar year) according to class I or class IIa indication (odds ratio, 1.17; 95% confidence interval, 1.10-1.24; P<0.001 and odds ratio, 1.12; 95% confidence interval, 1.05-1.20; P=0.001, respectively). Table 5 demonstrates the logistic regression analysis of factors associated with ACEI/ARB use as a class I indication. After adjustment, patients more likely to receive ACEI/ ARB therapy had a higher body mass index, had a medical history of diabetes mellitus, had CAD heart failure, were using tobacco, or underwent PCI. Patients less likely to receive ACEI/ARB therapy were women; were white; and had a medical history of atrial fibrillation, lung disease, or hypertension. Most strikingly, patients who received in-hospital CABG surgery or had renal insufficiency were least likely to receive ACEI/ARB therapy. Table 5 demonstrates the logistic regression analysis of factors associated with ACEI/ARB use as a class IIa indication. After adjustment, patients more likely to receive ACEI/ ARB therapy were older in age, had a prior MI, were using tobacco, underwent PCI, or were in larger hospitals. Patients less likely to receive an ACEI/ARB prescription were women; had a medical history of atrial fibrillation, hyperlipidemia, or depression; received in-hospital CABG; or were admitted to academic hospitals.
We performed a sensitivity analysis of ACEI/ARB in ACS excluding patients with CABG. Of this cohort, 55 699 met We performed an analysis of other performance measures reported in the GWTG-CAD program who present with ACS. In patients who met ACC/AHA class I criteria for ACEI/ARB therapy, 97.6% eligible patients (56 061/57 470) were discharged on aspirin, and 96.7% eligible patients (55 014/56 919) were discharged on a β-blocker. In patients who met ACC/AHA class IIa criteria for ACEI/ARB therapy, 98.2% eligible patients (18 374/18 715) were discharged on aspirin, and 95.9% eligible patients (17 151/17 887) were discharged on a β-blocker. As a nonpharmacological performance measure, we investigated the use of cardiac catheterization. The use was high overall (71.6% for ACC/AHA class I ACEI/ARB indicated patients; 73.9% for ACC/AHA class IIa ACEI/ARB indicated patients).
Discussion
The results of our study, derived from a large contemporary prospective national registry and quality improvement program, provide new insight into the frequency, temporal trends, and predictors of ACEI/ARB therapy in patients hospitalized with ACS. Interestingly, although the overall prescription rates for ACEI/ARB were higher than those previously reported, and increasing over the study period, 1 in 5 patients with ACC/AHA class I indication were still not receiving therapy. Furthermore, prescription rates were lower among particular patients who may be at greater risk of adverse outcomes. Significant independent predictors of lower use of ACEI/ARB for class I indications included in-hospital CABG, renal insufficiency, history of atrial fibrillation, white race, female sex, history of hypertension, and history of chronic obstructive pulmonary disease/asthma.
Benefits of ACEI/ARB Therapy
Renin-angiotensin system blockers initiated after MI reduce mortality, recurrent cardiovascular events, and new onset heart failure. 10, 19 Yet older data by Barron et al 16 (1994-1996) show only 31% of patients with an acute MI receive an ACEI at hospital discharge. In addition, the investigators reported only 41% with LV systolic dysfunction and 26% with an anterior MI received ACEI therapy. 16 More recently, randomized data would suggest no obvious difference between ACEI or ARB after ACS. 20 The present study is among the first to address the contemporary use and appropriateness of ACEI/ARB therapy in patients with ACS. As observed, there has been a substantial uptake of ACEI/ARB use in the past decade, which coincides with the implementation of quality assurance initiatives, such as the GWTG-CAD quality initiative program. 21, 22 These qualityof-care initiatives for the past decade have implemented best practice guideline-driven therapy as a measurement to promote quality improvement among hospitals. These accountability measures have benchmarked hospitals against best practice, allowing for marked improvement in evidence-based prescription patterns for American patients, which is reflected as contemporary therapy (as opposed to older data from Barron et al 16 ). Still, many patients with an ACC/AHA class I or class IIa indication are not receiving ACEI/ARB therapy on hospital discharge with an ACS. Similar results have been seen with other secondary prevention medications for ACS in GWTG-CAD patients. 23 However, in our study, the use of ACEI/ARB seems to be lower than that of other evidence-based therapies, such as aspirin and β-blockers. Thus, ongoing quality improvement initiatives are still necessary to help ensure appropriate secondary prevention is delivered.
ACEI/ARB Use in the Spectrum of ACS
ACEI/ARB prescription patterns were most aggressive in STEMI, with lower use in NSTEMI and unstable angina. The evidence for survival benefit with renin-angiotensin system blockade is most pronounced in STEMI, 2, 3 and our data support clinicians adherence with ≈90% of patients with ACC/AHA class I indication and 80% of patients with class IIa indication receiving ACEI/ARB therapy. However, recurrent events are more common with NSTEMI. 24 Yet our data show that fewer of these patients received ACEI/ARB prescriptions.
Predictors of ACEI/ARB Use
It is noteworthy that patients with inpatient CABG were less likely to receive an ACEI/ARB. After multivariable logistic regression, patients with an ACC/AHA class I indication for renin-angiotensin inhibition were ≈50% less likely to receive an ACEI/ARB after CABG. Our results confirm previous findings from observational studies, which report lower rates of ACEI/ARB after CABG and provide further evidence of a persistent care gap that requires immediate attention. [25] [26] [27] Given the deleterious effects of angiotensin II on the vascular endothelium, it would seem reasonable to block angiotensin production in the setting of CABG. However, there have been historical concerns linking ACEI as a cause of vasoplegic syndrome (low systemic vascular resistance and high cardiac output leading to vasodilatory shock) after CABG. 28 As well, the Ischemia Management with Accupril Post-bypass Graft via Inhibition of the Converting Enzyme (IMAGINE) trial found the use of postoperative ACE inhibitors started after CABG surgery did not improve clinical outcomes at 3 years. 29 Still, IMAGINE enrolled low-risk patients (without diabetes mellitus) undergoing CABG where the dose of ACE inhibitor that was started acutely in the postoperative period may have been excessive, resulting in hypotension. Other clinical trials have shown improved clinical outcomes with renin-angiotensin system blockers after CABG but are limited by their small sample size. 30, 31 Recently, a multinational observational prospective study found the use of renin-angiotensin inhibition after CABG results in improved cardiovascular and renal outcomes. 32 Thus, in such a high-risk patient population, ACEI/ ARB therapy should be considered after CABG. 33 Another striking imbalance in ACE/ARB prescription use was in patients with a history of renal insufficiency. Current evidence clearly supports the use of renin-angiotensin inhibitors in halting the progression of chronic kidney disease. 34, 35 Although ACEI/ARB therapy in end-stage renal disease is of concern, it is important to note that these patients were excluded from the current analysis (contraindication to ACEI/ ARB). In patients meeting an ACC/AHA class I indication, the median serum creatinine at discharge was 1.39 mg/dL. Yet we observed that patients with a history of renal insufficiency were less likely to receive renin-angiotensin inhibition. Again, after multivariate logistic regression, there was roughly a 40% reduction in the odds of receiving an ACEI/ ARB in patients with a history of renal insufficiency. The reasons for this paradox are unclear but suggest that clinicians are ambivalent to prescribe ACEI/ARBs possibly because of the concerns of worsening renal failure and potentiating hyperkalemia. Still, the risk is extremely low especially if the GFR is >40 mL/min per 1.73 m 2 and the potassium is in the normal range. 36 Perhaps further use in this subset of patients needs to be reinforced during ACS presentation.
Temporal Trends of ACEI/ARB Use
Reassuringly, ACEI/ARB prescription use increased early over the study time period. This finding is likely attributed to the ongoing acceptance and appreciation of the clinical benefits of ACEI/ARB therapy by clinicians treating patients with ACS. To add, for the past few decades, quality care initiatives, such as the Healthcare Financing Administration Cooperative Cardiovascular Project, the Veteran Affairs External Peer Review Program, the National Committee for Quality Assurance, the Joint Commission (formerly the Joint Commission on Accreditation of Healthcare Organizations), and the National Registry of MI, have helped benchmark participating hospitals and healthcare plans against best practice to promote evidence-based quality care. The GWTG-CAD program has helped promote optimal secondary prevention and has led to improvements in prescribing therapy over time. 37 Irrespective of age or sex, the GWTG quality improvement program has substantially improved adherence to guideline recommendations and has narrowed treatment gaps over time. 38 Since its inception in 2001, the GWTG program has facilitated evidence-based care and medication compliance using a hospital-based collaborative learning model, a Web-based patient management tool, and interactive multidisciplinary learning sessions to improve quality of care and implement best practice guideline therapy. 17, 21 With the use of guideline-based clinical pathways, best practice algorithms, discharge checklists, and educational tools, GWTG hospitals have demonstrated greater adherence to national guidelinerecommended therapies that are sustained over time. 37 However, there has been a plateau in the ACEI/ARB prescription pattern in the current GWTG analysis, which should prompt further hospital quality improvement and continued monitored adherence to secondary prevention guidelines to achieve 100% performance with all guideline-based care (ie, not only ACEI/ARB). Additional efforts may include personalized patient educational material, links to ambulatory care, and integrated electronic medical records to promote evidencebased practice. Perhaps ACEI/ARB should be considered a publicly reported metric to promote quality improvement and the use in MI, which could be an accountability measure in programs, such as the Joint Commission.
Limitations
This is an observational analysis, which is subject to residual confounding. However, our multivariable logistic regression analysis for predictors of ACEI/ARB use was robust, and efforts were made to balance clinical characteristics. Contraindications or intolerance to ACEI/ARB therapy may have been present but not documented, and as a result, this study may have underestimated treatments rates. The low rates of ACEI/ARB in patients with renal insufficiency may be, in part, because of the unknown severity or pattern of renal insufficiency during admission to the hospital. Every effort was made to exclude patients with end-stage renal disease with a contraindication to ACEI/ARB before our analysis. However, end-stage renal disease was defined at the discretion of the treating physician. Thus, it is conceivable that patients with a contraindication to ACEI/ARB because of poor renal function were included in the study. Still, our sensitivity analysis on a selected subgroup with available renal function would suggest that the number of patients with marked renal insufficiency (GFR<30 mL/min per 1.73 m 2 ) precluding ACEI/ARB is exceedingly low, recognizing that a portion of these patients would be on dialysis, which would allow for ACEI/ARB therapy. The low rates of ACEI/ARB prescription after ACS with CABG are notable, although considerations on appropriateness of ACEI/ARB use in a non-ACS CABG population cannot be addressed in our study. Our results, derived from hospitals participating in the GWTG-CAD quality improvement program, reflect the dominance of patients with ACS in this sample and may be the best -case scenario of which may differ from non-GWTG participating hospitals. Our results do not reflect the use in non-GWTG hospitals. Still, this should only reinforce the need for ACEI/ARB prescription use in patients with ACS because non-GWTG-CAD hospitals demonstrate lower guideline adherence to secondary prevention measures when compared with GWTG-CAD hospitals. 37 Killip class and discharge potassium were not collected. Finally, GWTG-CAD records physician prescribing behavior but does not address patient compliance issues, which may be the greatest predictor of clinical outcomes.
Conclusions
Results from this large national registry suggest that 1 in 5 eligible patients hospitalized for ACS failed to receive ACC/ AHA class I guideline-recommended ACEI/ARB therapy at hospital discharge, which raises concern. Certain patients with ACS, including those with renal insufficiency and those after CABG, were less likely to be treated. In an era where secondary prevention is paramount after ACS, it becomes imperative to ensure that appropriate medical therapy is initiated before discharge. Thus, additional quality improvement efforts focused on the use of ACEI/ARB therapy are warranted.
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